Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead

Executive Summary

Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.

You may also be interested in...



Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance

Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.

Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents

While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.

Biogen's Neuroscience Strategy Includes De-Risking The Pipeline

Biogen is laser-focused on leading neuroscience, but management also talked about ways to balance the high-risk nature of competing in the challenging therapeutic area.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099167

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel